Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GTAEXS617 |
Synonyms | |
Therapy Description |
GTAEXS617 inhibits CDK7, potentially resulting in cell cycle arrest, increased apoptosis, and reduced proliferation of tumor cells, and decreased tumor growth (Cancer Res (2022) 82 (12_Supplement): 3930). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GTAEXS617 | GTAEXS 617|GTAEXS-617 | CDK7 Inhibitor 16 | GTAEXS617 inhibits CDK7, potentially resulting in cell cycle arrest, increased apoptosis, and reduced proliferation of tumor cells, and decreased tumor growth (Cancer Res (2022) 82 (12_Supplement): 3930). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05985655 | Phase Ib/II | GTAEXS617 | Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (ELUCIDATE) | Recruiting | GBR | BEL | 0 |